Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler

C. Breuer · B. Wachall · K. Gerbeth · M. Abdel-Tawab · U. Fuhr

Received: 29 September 2012 / Accepted: 11 December 2012 / Published online: 5 January 2013 (c) The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract

Background Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability.

Objectives The current trial was conducted to explore pharmacokinetics and pharmacodynamics of two nebulized inhalative epinephrine doses (4 mg and 8 mg in aqueous solution) using a mobile pocket inhaler relative to intramuscular administration (0.3 mg) and placebo.

Methods This randomized, open-label, change-over pilot study involved eight young healthy men and women. Non-compartmental pharmacokinetic and pharmacodynamic parameters were calculated from epinephrine plasma concentrations and hemodynamic parameters.

Results Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L). Maximal concentrations were reached within approximately 15 min for all active treatments. Epinephrine effects for inhalative administrations on heart rates were significantly higher than those for the intramuscular or placebo administration, while no excessive effects occurred. Pronounced overall variability prohibited a definite assessment of relative bioavailability between treatments. However, results indicated that epinephrine concentrations obtained following the 8 mg inhalative dose were not inferior to those after 0.3 mg i.m.

Conclusions A relevant fraction of moist inhalation epinephrine doses is absorbed and mediates systemic effects. This suggests that administration of epinephrine via a suitable pocket inhaler device may be beneficial in ambulatory emergency treatment of systemic hypersensitivity reactions.

EudraCT number: 2010-021493-11

Keywords Acute allergic reaction · Anaphylaxis · Epinephrine · Inhalative · Intramuscular

Introduction

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death [1]. In addition to the immediate termination of further allergen exposure, epinephrine is the primary medical therapy for life-threatening allergic reactions [2]. Epinephrine antagonizes the symptoms of anaphylactic shock by increasing of heart rate (β1 adrenoceptors), myocardial contractility (β1), and peripheral vascular resistance (α1) by bronchodilatation with increased oxygen
absorption (β2) [3–7], and by decreasing further mast cell release of mediators of inflammation.

Epinephrine has a very low oral bioavailability which makes this form insufficient for therapeutic use [3–6]. Intravenous administration is often not feasible. Thus, intramuscular (i.m.) administration of epinephrine is used as first-line treatment and self-medication for serious hypersensitivity reactions, usually at doses of 0.3 mg in the lateral part of the thigh [3]. Despite the pivotal role of epinephrine in anaphylaxis, individuals are often reluctant to use self-injectable epinephrine (e.g. because of anxiety about using a needle) [8]. It has been reported that only 30–40 % of individuals in whom anaphylaxis occurred actually received epinephrine injections [9], and only 32 % of 101 families of food-allergic children correctly demonstrated the proper use of the device [10]. Moreover, application errors (e.g. intradermal injection) are common [11, 12]. Furthermore, for i.m. injection local vasoconstriction and a lowered blood supply of the muscles in the event of blood pressure drop-off may impair absorption, causing the effects of the medication to be delayed and prolonged [3–6].

Thus, there is a medical need for another rapidly acting route of epinephrine administration for serious hypersensitivity reactions, and to this end, inhalation of epinephrine might be considered. Inhalative administration offers direct local activity of epinephrine and rapid absorption. In particular, epinephrine inhalation is considered useful for anaphylactic reactions of the respiratory tract, but bioavailability studies of epinephrine inhalation are sparse in general and limited to metered dose inhaler applications that have been withdrawn from the market [13].

INFECTOKRUPP® Inhal (marketed in Germany) is an epinephrine solution for the treatment of allergic reactions of the upper airways containing 4 mg/mL epinephrine-HCl. It is currently indicated for acute dyspnoea in upper airway obstruction, especially laryngotracheobronchitis and allergic reactions [4]. In this method, epinephrine doses of up to 8 mg are inhaled [14]. The aim of this study was to investigate potential suitability of the administration of INFECTOKRUPP® Inhal by using a new battery driven mobile pocket inhaler (INFECTOPHARM Taschenvernebler, Omron Microair U22) for the treatment of acute allergic reactions in emergency situations. Thus, we explored pharmacokinetics and pharmacodynamics of 4 mg and 8 mg moist inhalation epinephrine doses relative to intramuscular administration (Anapen® 300 µg) and placebo inhalation.

Methods

The trial was conducted according to the principles of Good Clinical Practice [15] and in accordance with the ethical principles of the Declaration of Helsinki [16]. Approval was provided by the Ethics Committee of the Medical Association of North Rhine, Germany and the competent authority (EudraCT-number 2010-021493-11). Written informed consent was obtained from all participants.

This pilot trial was designed as a single site, randomized, placebo-controlled, open-label, four arm change-over study. The trial population comprised nine healthy Caucasians, aged between 28 and 53 years, weighing 60 kg or higher with a Body Mass Index of 19–29 kg/m². Dosing was done in a fasting state with the subjects in supine position with the upper half of the body semi-elevated, and at the same time in the morning for all treatments. In respective study periods, each participant received one of the following treatments as a single dose:

- **Treatment A (reference):** Anapen® (Dr. Beckmann Pharma GmbH, Seefeld, Germany), i.m. administration of 0.3 mL solution equivalent to 0.3 mg of epinephrine using the respective pen applicator placed at the anterolateral part of the musculus quadriceps femoris (application carried out and checked by a trained physician)
- **Treatments B or C (test treatments):** INFECTOKRUPP® Inhal (Infectopharm Arzneimittel und Consilium GmbH, Heppenheim, Germany), inhalative administration of 1 or 2 mL solution equivalent to 4 and 8 mg of L-epinephrine, respectively
- **Treatment D (placebo):** NaCl Inhalationslösung 0,9 % (PARI GmbH, Starnberg, Germany) inhalative administration of 2 mL solution, containing 0.9 % of sodium chloride in water

All inhalative treatments were administered using the Infectopharm Taschenvernebler® (Infectopharm Arzneimittel und Consilium GmbH, Heppenheim, Germany, identical to Omron Microair U22, Omron HealthcareEurope, Hoofddorp, The Netherlands), set to the on–off modus for the inhalation–exhalation procedure. The inhaler is characterized by a volumetric median particle diameter of 5.7± 0.06 µm, an inhalable fraction which is similar to the fine particle fraction of 40±1 %, and delivered doses of 27.5±0.2 % for 1 ml and 28.8±0.6 % for 2 ml administration volume, respectively (Infectopharm Arzneimittel und Consilium GmbH, data on file). Extensive training sessions were performed prior to dosing with each subject to safeguard correct use of the inhaler.

For the quantification of epinephrine in plasma, specific ClinRep® blood collection tubes were used (Recipe Chemicals and Instruments GmbH, München, Germany). Blood samples were taken from a catheter inserted beforehand three times before dosing and every minute following the start of administration up to 12 min, as well as 15, 20, 25, 30, 45, 60, 90, 120, 150 and 180 min. Blood samples were centrifuged at 4 °C and plasma was stored at −20 °C until analysis. The quantification of epinephrine was carried out...
using a validated, analytical high performance liquid chromatography-tandem mass spectrometry (HPLC-MS) method. The internal standard 1,2-13C DL-epinephrine was added to plasma, and samples were extracted using Recipe® sample preparation columns. Eluted samples were separated on a Phenomenex Kinetex™ column (Phenomenex, Aschaffenburg, Germany) at 20 °C using ammonium formiate-buffer / acetonitrile as the mobile phase. The MS ion source ESI was used at positive SIM mode. The lower limit of quantification (LLOQ) was 25 ng/L. Precision (coefficients of variation) and accuracy (bias) ranged between 1.6 % – 8.5 % and -7.6 % – 9.0 %, respectively.

Vital signs (systolic and diastolic blood pressure (BP) and heart rate (HR)) were measured oscillometrically prior to dosing, continuously from the start until 12 min after dosing and after each blood sampling (Dinamap™; Criticon, Tampa, FL, USA).

For calculations, concentrations below the LLOQ were set to ½ LLOQ (12.5 ng/L). Based on individual plasma concentrations (without baseline correction), AUC0-t(last), Cmax (primary pharmacokinetic parameters), AUC0.5h, AUC1.0h, AUC1.5h, tmax and MRTlast (secondary pharmacokinetic parameters) values were determined. In addition, the following pharmacodynamic parameters were calculated: Emax, AUEC0.5h, AUEC1.0h, AUEC1.5h and AUEClast for systolic and diastolic blood pressure and for heart rate (MRT: mean residence time, AUC: area under the curve, AUEC: area under the effect curve; indices apply for interval from (start of) dosing until the respective post-dose point of time).

Pharmacokinetic and pharmacodynamic parameters were calculated by noncompartmental methods and summarized by descriptive statistics. Comparison between treatments was done using the average bioavailability approach. To this end, an ANOVA with the factors sequence, subject (sequence), period, and treatment was performed for untransformed (only tmax) or log-transformed (all other parameters) data. The least-squares geometric means from the ANOVA were used to calculate the ratios and their 90 % confidence intervals (CIs) between corresponding treatments. The mean square error of the ANOVA was used as a variance estimate to calculate the 90 % CI around the point estimate of the true ratio for test (i.e. the two inhalative doses) relative to reference (i.m. administration) or placebo. Pharmacokinetic and bioavailability calculations were done using the WinNonlin® software Version 5.2 (PHARSIGHT Corporation, Mountain View, California, USA). All other analyses were performed using SAS® Version 9.1.3 or higher (SAS Institute, Cary, NC, USA). Primary comparisons were made between treatments B and C vs. A for main characteristics. Secondary comparisons included other parameters and comparisons to the placebo period. For the test over reference and/or test over placebo ratios, values of 70 % and 143 % were considered as lower and upper boundaries for “no relevant difference” between treatments. Statistically significant differences indicating a true effect irrespective of “relevance” were assumed if unity (i.e. 100 %) was not included in the 90 % confidence intervals for the treatment ratios. All results were considered as essentially descriptive because of the explorative pilot character of the study.

Results

Five male and three female healthy Caucasians completed the study. One subject dropped out because of difficulties with blood sampling. Duration of inhalation grouped by treatment is shown in Table 1.

Pharmacokinetic results

Pharmacokinetics of the subjects who completed the trial are shown in Table 1 (further data are provided in the supplementary material). Plots of median epinephrine plasma concentrations versus time profiles of epinephrine grouped by treatment are shown in Fig. 1.

Following epinephrine administration, a rapid increase in drug plasma concentrations could be observed in all active treatment periods. Plasma epinephrine concentrations declined rapidly and in most subjects reached the pre-dose levels or were below the LLOQ at 0.75–1.00 h post-dose. Mean exposure to epinephrine as derived from Cmax, partial AUCs and AUC0–t(last) was highest for the 8 mg inhalative dose and decreased from the 4 mg inhalative dose to the 0.3 mg i.m. dose, with all active treatments being significantly higher than placebo (Table 1, Fig. 1).

Pharmacodynamic results

In response to the administration of the study medication, heart rate increased, while blood pressure values were essentially unchanged (Table 1, see also supplementary material). The median effect on heart rate increased from placebo to 0.3 mg epinephrine as i.m. injection over 4 to 8 mg inhalative epinephrine (Fig. 2). HR decreased approximately to baseline values at about 1 h postdose, corresponding to the decline in epinephrine plasma concentrations.

Detailed comparison between treatments

The mean values of Cmax and AUC0–t(last) were considerably higher following inhalative epinephrine administrations compared to placebo. While statistically the high variability prevents rejection of the assumption that Cmax values have relevant differences to placebo in any direction, significantly
higher values for treatments B and C were observed with regard to AUC\textsubscript{0-t(last)} and partial AUCs (Table 2, Fig. 3).

Both C\textsubscript{max} and AUC\textsubscript{0-1.5h} values were higher when 4 or 8 mg epinephrine was administered via inhalation compared to administration of 0.3 mg epinephrine as i.m. injection. Ninety percent confidence intervals (CIs) of the ratios were all outside a 70–143 % range, thus relevant differences between treatments could not be excluded for these parameters (Table 2). Secondary pharmacokinetic variables confirm the results for the primary variables (Table 2, Fig. 3). The pronounced overall variability also prohibited a definite assessment of relative bioavailability between active treatments.

**Table 1** Descriptive statistics of pharmacokinetic and pharmacodynamic parameters following epinephrine administration grouped by treatment (uncorrected values, per protocol population of \(n=8\))

| Parameter                  | 0.3 mg i.m. geometric mean (CV %) | 4 mg inhal. geometric mean (CV %) | 8 mg inhal. geometric mean (CV %) | Placebo geometric mean (CV %) |
|----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|------------------------------|
| C\textsubscript{max} [ng/L] | 484 (162)                         | 513 (220)                         | 769 (78.9)                        | 252 (559)                    |
| t\textsubscript{max} [hr]a | 0.22 (0.25)                       | 0.29 (0.31)                       | 0.21 (0.13)                       | 0.11 (0.11)                  |
| AUC\textsubscript{0-0.5h} [ng*hr/L] | 70.7 (113)                  | 108 (230)                         | 162 (47.9)                        | 24.0 (131)                   |
| AUC\textsubscript{0-1h} [ng*hr/L] | 130 (78.9)                      | 148 (187)                         | 215 (43.6)                        | 40.0 (100)                   |
| AUC\textsubscript{0-1.5h} [ng*hr/L] | 156 (72.4)                      | 177 (164)                         | 233 (43.8)                        | 50.8 (84.6)                  |
| AUC\textsubscript{0-t(last)} [ng*hr/L] | 204 (66.6)                   | 236 (129)                         | 282 (43.2)                        | 81.6 (58.5)                  |
| MRT\textsubscript{last} [hr] | 0.899 (29.5)                      | 0.860 (34.6)                      | 0.721 (19.3)                      | 1.11 (40.8)                  |
| Duration of inhalation [min]a | Not applicable                   | 18.0 (5.90)                       | 27.0 (2.45)                       | 16.9 (2.23)                  |
| Heart rate E\textsubscript{max} [bpm] | 78.0 (10.8)                  | 88.2 (8.43)                       | 89.2 (10.9)                       | 87.4 (23.0)                  |
| Heart rate AUEC\textsubscript{0-0.5h} [bpm*hr] | 32.9 (8.50)                  | 38.4 (11.8)                       | 39.1 (7.80)                       | 32.5 (8.31)                  |
| Heart rate AUEC\textsubscript{0-1h} [bpm*hr] | 65.1 (8.25)                  | 70.8 (10.4)                       | 74.2 (7.45)                       | 64.7 (6.30)                  |
| Heart rate AUEC\textsubscript{0-1.5h} [bpm*hr] | 96.4 (7.44)                  | 103 (11.3)                        | 108 (9.65)                        | 96.3 (10.2)                  |
| Heart rate AUEC\textsubscript{0-t(last)} [bpm*hr] | 191 (6.69)                  | 200 (9.81)                        | 204 (10.2)                        | 185 (8.49)                   |
| Systolic BP E\textsubscript{max} [mm Hg] | 131 (12.5)                   | 133 (8.76)                        | 135 (9.60)                        | 133 (7.92)                   |
| Systolic BP AUEC\textsubscript{0-t(last)} [mm Hg*hr] | 338 (9.18)                   | 343 (11.0)                        | 343 (9.83)                        | 344 (9.65)                   |
| Diastolic BP E\textsubscript{max} [mm Hg] | 76.2 (10.6)                   | 77.5 (10.3)                       | 75.7 (10.1)                       | 80.2 (14.4)                  |
| Diastolic BP AUEC\textsubscript{0-t(last)} [mm Hg*hr] | 202 (7.38)                   | 204 (8.73)                        | 205 (8.94)                        | 211 (10.6)                   |

\(a\) arithmetic means and standard deviations (SD); \(AUC\) area under the concentration vs. time profile (indices apply for the postdose time interval); \(AUEC\) area under the effect curve; \(C_{\text{max}}\) maximal concentration; \(E_{\text{max}}\) maximal effect; \(MRT_{\text{last}}\) mean residence time calculated from concentrations up to the last point of observation; \(t_{\text{max}}\), time of \(C_{\text{max}}\); \(BP\) blood pressure. Fractional AUC values for blood pressure are presented in the supplementary material.

**Fig. 1** Median epinephrine plasma concentration versus time profiles grouped by treatment \((n=8)\) following administration of inhaled or intramuscular epinephrine or placebo. The time axis refers to the injection and/or to the start of inhalation.

**Fig. 2** Median heart rate versus time profiles grouped by treatment \((n=8)\) following administration of inhaled or intramuscular epinephrine or placebo. The time axis refers to the injection and/or to the start of inhalation.
Table 2 Comparison of pharmacokinetic and pharmacodynamic parameters of epinephrine for inhalative administration (B: 4 mg, C: 8 mg) relative to i.m. administration (A: 0.3 mg) or to placebo inhalation (D) (point estimates and 90 % confidence intervals)

| Parameter                      | Ratio Test B/Reference A (%) | Ratio Test C/Reference A (%) | Ratio Test B/Placebo D (%) | Ratio Test C/Placebo D (%) |
|--------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|
| C<sub>max</sub>                | 106.01                        | 158.95                        | 203.40                    | 304.98                    |
|                                | (48.23–232.97)                | (72.32–349.32)                | (61.37–674.19)            | (92.01–1010.89)           |
| AUC<sub>0–0.5h</sub>           | 152.21                        | 229.28                        | 448.72                    | 675.93                    |
|                                | (78.12–296.59)                | (117.67–446.76)               | (211.85–950.46)           | (319.12–1431.70)          |
| AUC<sub>0–1h</sub>             | 113.72                        | 165.80                        | 369.01                    | 538.00                    |
|                                | (66.86–193.41)                | (97.49–281.99)                | (192.37–707.81)           | (280.48–1031.98)          |
| AUC<sub>0–1.5h</sub>           | 113.06                        | 149.11                        | 348.13                    | 459.12                    |
|                                | (68.08–187.78)                | (89.78–247.65)                | (191.12–634.13)           | (252.05–836.29)           |
| AUC<sub>0–elast</sub>          | 115.83                        | 138.15                        | 289.64                    | 345.46                    |
|                                | (73.19–183.28)                | (87.30–218.61)                | (177.26–473.27)           | (211.42–564.48)           |
| MRT<sub>last</sub>             | 95.76                         | 80.27                         | 77.61                     | 65.05                     |
|                                | (78.85–116.28)                | (66.10–97.47)                 | (58.97–102.13)            | (49.43–85.61)             |
| Heart rate E<sub>max</sub>     | 113.15                        | 114.34                        | 100.98                    | 102.04                    |
|                                | (107.16–119.47)               | (108.29–120.73)               | (90.17–113.09)            | (91.12–141.28)            |
| Heart rate AUEC<sub>0–0.5h</sub> | 116.78                      | 118.96                        | 117.96                    | 120.16                    |
|                                | (109.29–124.78)               | (111.33–127.11)               | (113.07–123.06)           | (115.18–125.36)           |
| Heart rate AUEC<sub>0–1h</sub> | 108.77                        | 114.07                        | 109.42                    | 114.74                    |
|                                | (104.11–113.65)               | (109.18–119.18)               | (105.68–113.29)           | (110.82–118.81)           |
| Heart rate AUEC<sub>0–1.5h</sub> | 107.20                      | 111.79                        | 107.32                    | 111.91                    |
|                                | (103.76–110.76)               | (108.20–115.50)               | (101.31–113.69)           | (105.65–118.55)           |
| Heart rate AUEC<sub>0–elast</sub> | 104.56                      | 106.81                        | 108.03                    | 110.35                    |
|                                | (102.46–106.71)               | (104.66–109.00)               | (103.19–113.10)           | (105.40–115.52)           |
| Systolic BP E<sub>max</sub>    | 101.76                        | 103.13                        | 99.66                     | 101.00                    |
|                                | (92.70–111.72)                | (93.94–113.22)                | (94.75–104.82)            | (96.02–106.23)            |
| Systolic BP AUEC<sub>0–elast</sub> | 101.45                      | 101.36                        | 99.70                     | 99.60                     |
|                                | (95.37–107.92)                | (95.28–107.83)                | (96.18–103.34)            | (96.09–103.25)            |
| Diastolic BP E<sub>max</sub>   | 101.67                        | 99.24                         | 96.59                     | 94.28                     |
|                                | (95.75–107.95)                | (93.47–105.37)                | (92.33–101.06)            | (90.12–98.64)             |
| Diastolic BP AUEC<sub>0–elast</sub> | 101.19                      | 101.41                        | 96.88                     | 97.09                     |
|                                | (96.29–106.35)                | (96.50–106.58)                | (93.23–100.68)            | (93.44–100.89)            |

AUC area under the concentration vs. time profile (indices apply for the postdose time interval); AUEC area under the effect curve; C<sub>max</sub> maximal concentration; E<sub>max</sub> maximal effect; MRT<sub>last</sub> mean residence time calculated from concentrations up to the last point of observation; BP blood pressure; *blood pressure did not show consistent differences between treatments, fractional AUECs are presented in the Supplementary Material.

However, non-inferiority in drug exposure of 8 mg epinephrine via inhalation compared to 0.3 mg i.m. injection was indicated with regard to truncated and complete AUC values (Table 2, Fig. 3; see also supplementary material).

The comparison of pharmacodynamic parameters derived from heart rate values clearly showed significantly higher values for the 4 or 8 mg epinephrine inhalations compared to 0.3 mg i.m. injection, while the entire confidence intervals were always completely within the predefined “no relevant difference” boundaries of 0.7–1.43. While clinical translation of these formal boundaries may be debatable, the magnitude of both mean and maximal heart rate effects suggests that these do not generate a safety concern for inhalative epinephrine administration (Table 2).

Figure 3 illustrates the comparison between treatments for the parameter expected to be most representative and sensitive to treatment differences, i.e. the AU(E)C for the initial 30 min after (start of) administrations.

In summary, pharmacokinetic bioequivalence between inhalative and i.m. preparations could not be proven, while the assumption of relevant pharmacodynamic differences could formally be rejected based on the predefined criteria. A closer look however indicates that concentrations obtained following 8 mg inhalative dose are at least not relevantly inferior to those after 0.3 mg i.m. injection (i.e. the lower limit of the 90 % CI is above 70 %), while changes in heart rate do not include unity, suggesting that the effects of inhaled epinephrine exceed those of i.m. epinephrine,
without reaching a magnitude suggestive of excessive cardiac risk.

Safety results

Overall, the study medication was well tolerated. The frequency of treatment-emergent adverse events (TEAEs) including those causally related to the trial drug administration (adverse drug reaction, ADRs) was higher following Treatments B and C compared to Treatment A and Placebo D. However, the nature and intensity of TEAEs (n=77) and ADRs (n=37, most assessed as mild) was very similar between treatments. Most of these adverse events occurred within minutes after the start of epinephrine administration and were of short duration. They reflected the known pharmacological effects such as tremor, palpitations, dizziness, tension or fear and headache. No local mucosal adverse effects at the site of epinephrine inhalation were reported by the volunteers. No serious adverse events occurred.

Despite the relatively high inhalative doses of epinephrine applied in the study and significantly higher HRs as a manifestation of epinephrine hemodynamic effects following Treatments B and C, there were no excessive changes putting subjects at unacceptable risk. During the trial, there were no cases when inhalation should be stopped due to an unacceptable rise in systolic BP or in HR. Maximum observed values were 130 bpm for HR (following placebo) and 159 mmHg for systolic BP (following inhalation of the 8 mg dose).

Discussion

This trial shows that inhalative administration of epinephrine using the combination of a marketed epinephrine solution with a mobile inhaler can effectively deliver the drug into the systemic circulation. The results indicate that epinephrine plasma concentrations and haemodynamic (HR) effects of 8 mg inhalative epinephrine dose are at least not inferior to those following a 0.3 mg epinephrine dose as i.m. injection, without causing relevant differences in the nature and severity of adverse effects. The high inhalative doses in comparison to intramuscular doses were required because of the reportedly low bioavailability of inhalative epinephrine (see below).

Pharmacokinetic data on inhalative epinephrine is limited, and existing studies used metered-dose aerosols. Therefore one might suppose that a high fraction of epinephrine was swallowed, especially when not using spacers. As shown by several authors [17–21], inhaled epinephrine is

Table 3 Doses and plasma concentrations of epinephrine reported in clinical pharmacology trials

| Reference | Healthy volunteers | dose | C_{max} | ΔHR* | ΔSBP* | Limitations |
|-----------|--------------------|------|---------|------|-------|-------------|
| (17) 8    | 3.0 mg pressurized aerosol | 400 ng/L | + 12 bpm | + 10 mmHg | Epinephrine absorption was less complete and shorter in duration than by sc injection |
| (18) 12   | 1.5 mg metered-dose aerosol | 500 ng/L (5 min) | + 10 bpm | not presented | Gastrointestinal side effects were dose-limiting |
| (20) 6    | 2.4 mg pressurized aerosol | 300 ng/L (1 min) | + 9 bpm | + 12 bpm | not presented |
| (19) 9    | 3.0 mg aerosol spray inhalation | 2300 ng/L (1 min) | + 15 bpm | + 10 mmHg | Systemic absorption was more variable after inhalation than with sc administration |
| (21)* 19**| 0.078 mg/kg pressurized metered-dose inhaler | 1822 ng/L (32.7 min) | not presented | not presented | High number of inhalations required, bad taste |

*Data are given as means, ΔHR: change in heart rate, bpm: beats per minute, ΔSBP: change in systolic blood pressure

**asymptomatic children with a history of anaphylaxis
inhaled epinephrine tended to be dose dependent and were short-lasting. Pharmacokinetic results of the moist inhalation of epinephrine of this trial provide plasma concentrations which are in the same order of magnitude to those reported in previous studies in healthy volunteers with other inhalative systems (Table 3). Side effects or limitations like those reported in references 17–21 were not observed (Table 3).

In healthy volunteers with normal blood pressure, changes in HR rather than in systolic and diastolic BP appear to be more sensitive because blood pressure is regulated by numerous compensatory mechanisms of which modifying HR is an important one [17, 19, 22]. Furthermore, the vasodilatory effect of epinephrine via β2-adrenoceptors may have indirectly contributed to the increase in heart rate. Finally, a direct effect on cardiac β-adrenoceptors, which would be caused by higher local concentrations of epinephrine upon inhalative administration, cannot be excluded. This may explain why in the present study pharmacodynamic effects were limited to heart rate changes, while in other studies an increase in blood pressure was also seen (Table 3). The more pronounced tachycardia for the inhalative administration also suggests that concentration in venous blood samples may not be able to fully capture local concentrations in the lung and in the heart.

Usually use of epinephrine immediately after allergen exposure is effective in the treatment of anaphylaxis. In the first-aid treatment of anaphylaxis, delay in epinephrine administration increases the risk for fatal outcomes including death [23–26]. The present study supports the idea that inhalative administration may be an alternative to intramuscular administration. Individuals are often reluctant to use self-injectable epinephrine [27–30], therefore compliance of epinephrine autoinectors could be inferior to epinephrine inhalers and thus inhalation often would be confronted with non-therapy. Here, continuous inhalative administration of epinephrine seems to provide appropriate systemic exposure within several minutes, persisting longer after prolonged inhalation of the 2 ml dose. In addition, administration of inhaled epinephrine appears to be safe and it is well controllable in case of adverse effects because any further systemic exposure can be stopped immediately. There are some intrinsic limitations for the inhalative use of epinephrine as studied here, because the patient needs to be able to apply an appropriate inhalation technique and to maintain a sufficient duration of the inhalation. The high variability of plasma epinephrine concentrations across the subjects may in part be caused by administration technique or interindividual variability of absorption rate and inactivation. Its clinical relevance remains to be assessed. On the other hand, it has to be emphasized that the onset after epinephrine inhalation was as fast as for the i.m. application route. In addition, patients may be less reluctant to use an inhalative system upon exposure to an allergen prior to the development of symptoms and may continue or repeat dosing as required.

In conclusion, this primarily exploratory trial indicates that following administration of 4 or 8 mg of L-epinephrine (INFECTOKRUPP® Inhal) via inhalation using the “INFECTOPHARM Taschenvernebler”, at least equal systemic exposure and more pronounced pertinent hemodynamic effects with a similar tolerability profile can be achieved compared to 0.3 mg epinephrine (Anapan®) as i.m. injection. These data suggest that moist inhalative epinephrine administration via a suitable inhaler device may provide therapeutic efficacy in ambulatory emergency treatment of systemic hypersensitivity reactions. It remains to be studied whether this approach is appropriate in a wider population of patients.

Role of the funding source This study was funded by Infectopharm Arzneimittel und Consilium GmbH, who guided design of the study and organized data analysis. The collection of data was done by the personnel of ITECRA GmbH & Co. KG. Infectopharm participated in the interpretation of data, the writing of the manuscript and in the decision to submit the manuscript for publication.

Conflict of Interest Statement Mona Abdel-Tawab and Uwe Fuhr conducted previous studies as work for hire for Infectopharm Arzneimittel und Consilium GmbH. Cornelia Breuer, and Kathleen Gerbeth have no conflicts to report. Bertil Wachall is an employee of Infectopharm Arzneimittel und Consilium GmbH.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Sampson HA, Munoz-Furlong A, Campbell RL et al (2006) Second symposium on the definition and management of anaphylaxis: summary report-second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol 117(2):391–397
2. Lieberman P, Nicklas RA, Oppenheimer J et al (2010) The diagnosis and management of anaphylaxis practice parameter. J Allergy Clin Immunol 126(3):477–480, e1–42
3. SmPC of Anapen®, DR. BECKMANN Pharma GmbH. 2006
4. SmPC of INFECTOKRUPP® Inhal, INFECTOPHARM Arzneimittel und Consilium GmbH. 2008
5. SmPC of PARI NaCl Inhalationslosung (0.9 %), PARI GmbH. 2008
6. SmPC of PARI NaCl Inhalationslosung (0.9 %), PARI GmbH. 2009
7. Schlegel C, Fux R, Biedermann T (2009) Epinephrine inhalers in emergency sets of patients with anaphylaxis. J Dtsch Dermatol Ges 7(5):420–426
8. Frew AJ (2011) What are the ‘ideal’ features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy Jan;66(1):15–24
9. Simons FE (2004) First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 113(5):837–844
10. Sicherer SH, Forman JA, Noone SA (2000) Use assessment of self-administered epinephrine among food-allergic children and pediatricians. Pediatrics 105(2):359–362
11. Simons FE, Lieberman PL, Read EJ Jr, Edwards ES (2009) Hazards of unintentional injection of epinephrine from autoinjectors: a systematic review. Ann Allergy Asthma Immunol 102(4):282–287
12. Simons FE, Edwards ES, Read EJ, Jr., Clark S, Liebelt EL (2010) Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol Feb;125(2):419–23 e4.
13. Muller UR, Bonifazi F, Przybilla B et al (1998) Withdrawal of the medihaler-epi/adrenaline medihaler: comments of the subcommittee on insect venom allergy of the EAACI. Allergy 53(6):619–620
14. Davies. Pharmacokinetics of inhaled substances. Dep of Clinical Pharmacology, Royal Postgraduate Medical School, University of London 1975:44–9
15. Note for Guidance on Good Clinical Practice (ICH Topic E6). CPMP/ICH/135/95, January 1997; EMEA July 2002
16. World Medical Association. Declaration of Helsinki, resolved in Helsinki in 1964, supplemented or amended in Tokyo 1975, Venice 1983, Hong Kong 1989, Somerset West, Republic of South Africa 1996, Edinburgh, Scotland 2000, Tokyo 2004, Seoul 2008
17. Dahlof C, Mellstrand T, Svedmyr N (1987) Systemic absorption of adrenaline after aerosol, eye-drop and subcutaneous administration to healthy volunteers. Allergy 42(3):215–221
18. Heilborn H, Hjemdahl P, Daleskog M, Adamsson U (1986) Comparison of subcutaneous injection and high-dose inhalation of epinephrine-implications for self-treatment to prevent anaphylaxis. J Allergy Clin Immunol 78(6):1174–1179
19. Mellem H, Lande K, Kjeldsen SE et al (1991) Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection. Br J Clin Pharmacol 31(6):677–681
20. Warren JB, Doble N, Dalton N, Ewan PW (1986) Systemic absorption of inhaled epinephrine. Clin Pharmacol Ther 40(6):673–678
21. Simons FE, Gu X, Johnston LM, Simons KJ (2000) Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis. Pediatrics 106(5):1040–1044
22. Blankestijn PJ, Man in’t Veld AJ, Tulen J et al (1988) Twenty-four hour pressor effect of infused adrenaline in normotensive subjects: a randomized controlled double-blind cross-over study. J Hypertens Suppl 6(4):S562–S564
23. Bock SA, Munoz-Furlong A, Sampson HA (2001) Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 107 (1):191–193
24. Pumphrey RS (2000) Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 30(8):1144–1150
25. Pumphrey RS (2004) Fatal anaphylaxis in the UK, 1992–2001. Novartis Found Symp 257:116–128, discussion 28–32, 57–60, 276–85
26. Sampson HA, Mendelson L, Rosen JP (1992) Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 327(6):380–384
27. Edwards MR, Overstall S, Green DS (2004) Response to: accidental epipen injection into a digit-the value of a Google search. Ann R Coll Surg Engl 86(6):490
28. Kaspersen J, Vedsted P (1998) Accidental injection of adrenaline in a finger with EpiPen. Ugeskr Laeger 160(45):6531–6532
29. Schintler MV, Arbab E, Aherer W, Spendel S, Scharnagl E (2005) Accidental perforating bone injury using the EpiPen autoinjection device. Allergy 60(2):259–260
30. McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP (2003) Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ 327(7427):1332–1335